Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability

Carlo Fumagalli MD, Andrea Ungar MD, PhD, Renzo Rozzini MD, Matteo Vannini MD, Flaminia Coccia MD, Giulia Cesaroni MD, Francesca Mazzeo MD, Nicoletta D’Ettore MD, Chiara Zocchi MD, Luigi Tassetti MD, Alessandro Bartolini MD, Federico Lavorini MD, PhD, Rossella Marcucci MD, PhD, Iacopo Olivotto MD, Laura Rasero PhD, MSN, RN, Francesco Fattorilli MD, Stefano Fumagalli MD, PhD, Niccolò Marchionni MD

A B S T R A C T

Objectives: To assess the association of pre-morbid functional status [Barthel Index (BI)] and frailty [modified Frailty Index (mFI)] with in-hospital mortality and a risk scoring system developed for COVID-19 in patients ≥75 years diagnosed with COVID-19.

Setting and Participants: Data on consecutive patients aged ≥75 years admitted with COVID-19 at 2 Italian tertiary care centers were collected from February 22 to May 30, 2020.

Methods: Overall, 221 consecutive patients with COVID-19 aged ≥75 years were admitted to 2 hospitals in the study period and were included in the analysis. Clinical, functional (BI), frailty (mFI), laboratory, and imaging data were collected. Mortality risk on admission was assessed with the COVID-19 Mortality Risk Score (COVID-19 MRS), a dedicated score developed for hospital triage.

Results: Ninety-seven (43.9%) patients died. BI, frailty, age, dementia, respiratory rate, PaO2/FiO2 ratio, creatinine, and platelet count were associated with mortality. Analysis of the area under the receiver operating characteristic (AUC) indicated that the predictivity of age was modest and the combination of BI, mFI, and COVID-19 MRS yielded the highest prediction accuracy (AUC_{COVID-19 MRS} + BI + mFI vs AUC_{Age}: 0.87 vs 0.59; difference: +0.28, lower bound–upper bound: 0.17–0.34, P < .001).

Conclusions and Implications: Premorbid BI and mFI are associated with mortality and improved the accuracy of the COVID-19 MRS. Functional status may prove useful to guide clinical management of older individuals.

© 2021 AMDA – The Society for Post-Acute and Long-Term Care Medicine.
population is limited. Italy was the first country outside Asia to be heavily plagued by the virus, with more than 1 million confirmed cases since January 31, 2020, with many older individuals involved.

Aim of this study was to assess the association of functional profile on mortality in patients ≥75 years admitted for COVID-19 to 2 tertiary care centers located in Lombardy and Tuscany, and to analyze whether it may help stratify prognosis according to the COVID-19 Mortality Risk Score (COVID-19 MRS), a scoring system developed for rapid triage evaluation.

Methods

Study Design

This is a retrospective observational study. The clinical history, laboratory, and imaging variables of patients consecutively admitted with proven COVID-19 to 2 Italian tertiary hospitals located respectively in Northern and Central Italy from February 22 to May 30, 2020, were collected on admission and reviewed. Only patients aged ≥75 years were included in the present analysis. Overall, 616 patients with COVID-19 were admitted to the 2 hospitals over the selected period, and the 221 aged ≥75 years constituted our study population.

Patient Characteristics

Hospital characteristics and organization during the pandemic wave, as well as methods used to collect clinical, laboratory, and imaging variables for each patient into a unique database, have been previously described. Variables assessed on hospital admission for each patient were collected from electronic charts and included demographics, number of drugs prescribed prior to admission, cardiovascular risk factors (smoking history, hypertension, diabetes), and data on comorbidities (including information on active and nonactive cancer and cardiovascular and pulmonary diseases).

Functional status 2 weeks prior to hospitalization was routinely assessed with the Barthel Index by interviewing the patient and relatives by phone calls, in which lower values correspond to poorer functional status and to poorer prognosis in the general older population. Briefly, the Barthel Index summarizes functional independence in feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfers, mobility, and stairs. Frailty was assessed based on the modified Frailty Index (mFI) created by Saxton and Velanovich by mapping 11 variables (nonindependent functional status, history of diabetes mellitus, chronic obstructive pulmonary disease or pneumonia, heart failure, myocardial infarction, angina or coronary revascularization, hypertension, peripheral vascular disease, presence of impaired sensorium, TIA or cerebrovascular event without or with deficit) present in the Canadian Study of Health and Aging Frailty Index. Frailty was defined by a score, equal to the ratio between present on total conditions, >0.36. Information on respiratory support and drugs prescribed during hospital stay were collected as well. Six medical doctors collected the data into a unique database and independently reviewed their consistency. Data were last updated on May 30, 2020.

In accordance with Ethics Committees’ indications at both hospitals, which approved data collection and granted a waiver of informed consent from study participants, patients’ identity was anonymized, and information protected by password.

Clinical Severity on Admission

Baseline clinical severity was assessed with the COVID-19 Mortality Risk Score (COVID-19 MRS), a rapid, operator-independent clinical tool developed to stratify mortality risk at triage. The 6 items of the score are age, number of comorbidities, respiratory rate, Pao2/Fio2, serum creatinine, and platelet count; each item is scored from 1 to 3 according to tertiles of phenotype severity. As previously described, mortality risk is classified as low (<10), intermediate (11-13), and high (≥14).

Study Outcomes

Predictive accuracy of the COVID-19 MRS and the association of disability (defined as a Barthel Index <75) and frailty with in-hospital mortality and their impact on the COVID-19 MRS risk stratification capability were the primary outcomes.

Statistical Analysis

Continuous variables, reported as mean ± standard deviation or as median with interquartile range, respectively for normal and non-normal distributions, were compared between groups (“survivor” vs “nonsurvivor” status) with t test or nonparametric tests, as appropriate. Categorical variables, reported as counts and percentages, were compared between groups with χ2 test, or Fisher exact test when the expected cell count was less than 5.

Cox multivariable regression analysis (with backward stepwise deletion) was used to assess determinants of mortality. All variables with P < .10 were entered into the multivariable models, and a 2-sided P < .05 was considered statistically significant. Receiver operating characteristic analysis was used to compare prediction performance of the COVID-19 MRS with and without disability (as expressed by the Barthel Index) and frailty. Statistical analysis was performed using the SPSS, version 27.0, statistical package for Macintosh (IBM, Armonk, NY).

Results

Baseline Clinical Characteristics

As of May 30, a total of 124 (56.1%) of 221 patients [overall median age 82 (78-86) years, 60.6% men] had been discharged from hospital alive, whereas 97 (43.9%) had died.

The demographic and clinical characteristics of nonsurvivors and survivors are reported in Table 1. Nonsurvivors were significantly older, with no differences between men and women. Cardiovascular risk factors and comorbidities were similarly distributed in the 2 study groups. Nonsurvivors presented a higher degree of functional impairment (lower Barthel Index), frailty (as mFI), and dementia. Previous use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was similar in both groups. At triage, nonsurvivors presented a higher COVID-19 MRS and more frequently reported preadmission insomnia. Other symptoms before admission were similarly prevalent in the 2 groups.

Laboratory and Imaging Findings

Laboratory findings are presented in Supplementary Table 1. In the population as a whole, the median Pao2/Fio2 ratio was 260 (interquartile range 204-406), and values < 200 were associated with a higher mortality. Lymphopenia was present in 69% of the population. Nonsurvivors had a lower platelet count, higher levels of serum creatinine, lactate dehydrogenase, and C-reactive protein. Furthermore, nonsurvivors presented with worse baseline inflammatory response. Chest radiograph was abnormal in 92.5% of cases.

Medical Management and Clinical Outcomes

Overall, 79.6% of patients received liberal oxygen and only 11.8% and 5.5% received, respectively, noninvasive and invasive ventilation,
more frequently nonsurvivors (Supplementary Table 1). Although
antibiotics had been prescribed more frequently to nonsurvivors,
prescription of heparin, hydroxychloroquine, and antiviral agents
(combination of lopinavir/ritonavir) were all more frequently pre-
scribed to survivors. Notably, there was no association of Barthel Index
with treatment strategies (Supplementary Table 2).

Determinants of Mortality and Outcome Prediction by the COVID-19
MRS

Cox multivariable regression analysis (Table 2, Model 1) indicated
that absence of disability (higher Barthel index), PaO2/FiO2 ratio, and
platelet count were positively associated, whereas age, presence of
dementia, and higher respiratory rates and serum creatinine levels
were negatively associated with survival. Similarly, a higher Barthel
Index and lack of frailty were associated with a better outcome after
adjusting for COVID-19 MRS risk category (Table 2, Model 2).

Analysis of the area under the receiver operating characteristic
(AUC) indicated that the predictive power for mortality of age alone
was modest.

Comparison of AUCs (Figure 1A) revealed that the overall predic-
tion quality increased by using the COVID-19 MRS score (AUCCOVID-19
MRS vs AUCAge: 0.81 vs 0.59; difference: +0.21, lower bound < 0.12-0.34;
P < .001) and the score combined with the BI and
mFI (AUCCOVID-19 MRS + BI + mFI vs AUCCOVID-19 MRS: 0.87 vs 0.81;
difference: +0.06, lower bound–upper bound: 0.02-0.08, P = .005;

Table 1
Clinical Characteristics on Hospital Admission by Survival Status

| Demographic Characteristics | Overall (N = 221) | Nonsurvivors (n = 97) | Survivors (n = 124) | P       |
|-----------------------------|-------------------|----------------------|---------------------|---------|
| Age, median (IQR)           | 82 (78-86)        | 83 (79-87)           | 80 (77-85)          | .011    |
| Age >90 y                   | 23 (10.4)         | 11 (11.3)            | 12 (9.7)            | .69     |
| Sex, male                   | 134 (60.6)        | 62 (63.9)            | 72 (58.1)           | .38     |
| Smoking history             | 56 (25.3)         | 18 (18.6)            | 38 (30.6)           | .043    |
| Hypertension                | 113 (51.2)        | 51 (52.6)            | 62 (50.0)           | .61     |
| Diabetes mellitus           | 78 (35.3)         | 41 (42.3)            | 37 (29.2)           | .06     |
| CV disease                  | 107 (48.4)        | 50 (51.5)            | 57 (46.0)           | .41     |
| Previous stroke/TIA         | 17 (7.7)          | 11 (11.3)            | 6 (4.8)             | .07     |
| COPD                        | 36 (16.3)         | 13 (13.4)            | 23 (18.5)           | .30     |
| Cancer                      | 34 (15.4)         | 19 (19.5)            | 15 (12.0)           | .25     |
| Depression                  | 37 (16.7)         | 19 (19.5)            | 18 (14.5)           | .59     |
| Dementia                    | 42 (19.0)         | 32 (33.0)            | 10 (8.1)            | <.001   |
| Comorbidities*, n, median (IQR) | 3 (2-5)         | 4 (2-6)              | 3 (2-5)             | .65     |
| Frail                       | 79 (35.7)         | 43 (44.3)            | 36 (29.0)           | .019    |
| Barthel Index, mean ± SD    | 80 ± 23           | 72 ± 27              | 82 ± 18             | .009    |
| <75                         | 102 (46.2)        | 69 (71.1)            | 33 (26.6)           | <.001   |
| ≥75                         | 119 (53.8)        | 28 (28.9)            | 91 (73.4)           | .015    |
| Drugs, median (IQR)         | 5 (3-8)           | 3 (3-9)              | 4 (2-7)             | .010    |
| ACE-i/ARBs                  | 84 (38.2)         | 32 (33.0)            | 52 (41.9)           | .20     |
| COVID-19 MRS                |                    |                      |                     |         |
| Low (≤10)                   | 16 (7.2)          | 2 (2.1)              | 14 (11.3)           | <.001   |
| Intermediate (11-13)        | 90 (40.7)         | 22 (22.7)            | 68 (54.8)           | .015    |
| High (≥14)                  | 115 (52.1)        | 73 (75.3)            | 42 (33.9)           |         |

Signs and symptoms

| Fever                       | 179 (80.9)        | 82 (84.5)            | 97 (78.2)           | .13     |
| Cough                       | 99 (44.7)         | 45 (46.3)            | 54 (43.5)           | .66     |
| Dyspnea                     | 103 (46.6)        | 50 (51.5)            | 53 (42.7)           | .16     |
| Respiratory rate, median (IQR) | 22 (20-28)       | 28 (21-33)           | 20 (18-24)          | <.001   |
| Insomnia                    | 37 (16.7)         | 21 (21.6)            | 16 (12.9)           | .043    |
| Diarrhea                    | 22 (10.0)         | 9 (9.3)              | 13 (10.5)           | .79     |
| Syncope                     | 18 (8.1)          | 10 (10.3)            | 8 (6.5)             | .298    |
| Altered mental status       | 24 (10.9)         | 11 (11.3)            | 13 (10.5)           | .80     |

ACE-i, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; COPD, chronic obstructive pulmonary disease; CV, cardiovascular disease; IQR, interquartile range; SD, standard deviation; TIA, transient ischemic attack.

Unless otherwise noted, values are n (%).

*Comorbidities is a composite variable including hypertension to dementia.

Table 2
Cox Multivariable Regression Analysis of Determinants of In-Hospital Mortality

| Variables                          | Model 1: Clinical and Laboratory Variables | Model 2 | Variables                          | Model 1: Clinical and Laboratory Variables | Model 2 | P       |
|-----------------------------------|-------------------------------------------|---------|-----------------------------------|-------------------------------------------|---------|---------|
| HR                                | 95% CI                                    | P       | HR                                | 95% CI                                    | P       |         |
| Barthel Index, (≥75 vs < 75)      | 0.383 (24.0-0.62)                         | <.001   | COVID-19 MRS, (for unitary increase) | 1.49 (1.33-1.69)                         | <.001   |         |
| Age (per year increase)           | 1.06 (1.01-1.11)                          | .015    | Barthel Index, (≥75 vs < 75)      | 0.35 (0.22-0.57)                         | <.001   |         |
| Dementia (no vs yes)              | 0.52 (0.31-0.88)                          | .015    | Fraility (no vs yes)              | 0.60 (0.39-0.94)                         | .024    |         |
| RR (per breaths/min increase)     | 1.06 (1.02-1.09)                          | <.001   |                                  |                                           |         |         |
| PaO2/FiO2 (per unit increase)     | 0.995 (0.994-0.999)                       | .019    |                                  |                                           |         |         |
| Creatinine (per mg/dl increase)   | 1.20 (1.04-1.39)                          | .012    |                                  |                                           |         |         |
| Platelets (10^12/L per unit increase) | 0.997 (0.992-0.998)                 | .003    |                                  |                                           |         |         |

CI, confidence interval; HR, hazard ratio; RR, respiratory rate.
Variables excluded (P > .10) from Model 1: frailty, number of drugs, C-reactive protein, and number of comorbidities.
Severity and level of comorbidity, in determining the risk of death in power of the COVID-19 MRS, with a were closely associated to the outcome and added to the predictive Overall, our results underscore the importance of an integrated an AUC of 0.59, frailty (as expressed as the mFI) and functional pro
tality. Furthermore, although age had a modest predictive role, with
the number of comorbidities, were associated with in-hospital mor-

Fig. 1. ROC analysis. (A) Comparison of COVID-19 Mortality Risk Score (COVID-19 MRS) ROC curves with and without Barthel Index (BI) and modified Frailty Index (mFI) and Age. (B) Coordinates of the ROC curve for the COVID-19 MRS (all values for sensitivity and 1 − specificity are percentages). ROC, receiver operating characteristic.

Discussion

In this study, almost 50% of patients aged >75 years admitted for COVID-19 died during hospitalization. Case fatality rates have been reported variably and are approximately 0.1% in children, but as high as 15% in old Chinese patients and even higher in older Italians or US citizens. Viral shedding, atypical symptoms, lower cardiorespiratory reserve, and a proinflammatory status have been all postulated as potential causes of such an age-associated poor prognosis.

In our study, worse functional profile (moderate to severe disability as expressed by the Barthel Index), age, dementia, respiratory rate, platelet count, serum creatinine, and PaO2/FiO2 ratio, but not the number of comorbidities, were associated with in-hospital mortality. Furthermore, although age had a modest predictive role, with an AUC of 0.59, frailty (as expressed as the mFI) and functional profile were closely associated to the outcome and added to the predictive power of the COVID-19 MRS, with a final AUC of 0.87. This confirms the relevance of overall physical functioning, above and beyond disease severity and level of comorbidity, in determining the risk of death in older populations. This message has direct clinical implications when choosing therapeutic strategies at hospital admission: older patients should be routinely assessed for frailty and disability in order to identify appropriate therapeutic strategies. The burden of COVID–19 pandemic in Italy was unique and overwhelming, posing the healthcare system into strain and presenting with difficult challenges. Overall, our results underscore the importance of an integrated assessment to avoid misplaced health priorities and ageism.

Compared with other series of patients with COVID–19 that included younger individuals, our patients presented with an average greater burden of chronic comorbidities and, accordingly, of prescribed drugs. Advanced age per se and associated chronic comorbidities have been identified as the strongest predictors of mortality in patients diagnosed with COVID–19. In our patients older than 75 years, functional profile 2 weeks prior to hospitalization and the mFI predicted in-hospital mortality and increased the predictive power of the COVID–19 MRS, confirming the importance of comprehensive geriatric assessment as part of the admission evaluation.

As a case in point, in older patients hospitalized for pneumonia, functional status and frailty were independently associated with short- and long-term mortality. Frailty, although difficult to define and quantify objectively, is generally intended as an impairment in muscular function associated with reduced homeostatic capacity in front of acute stressors and is reported as an accurate predictor of adverse health outcomes, both in acute care settings and in elective procedures.

More recently, a report from the COPE cohort study showed that in individuals with COVID–19, length of hospital stay and mortality were associated with frailty. Our results extend this concept by showing that the definition of the functional profile prior to COVID–19 may refine the assessment of prognosis defined by a disease-specific prognostic score such as the COVID–19 MRS.

Limitations

Some limitations of our study have to be acknowledged. First, the observational nature of our analysis does not allow to draw any firm conclusion about clinical determinants of mortality and associations with therapeutic strategies that, moreover, were clearly adapted over time. In addition, some laboratory parameters, which proved to be of prognostic relevance in other studies, were not collected for all individuals in our sample, possibly as a consequence of variable severity of some clinical pictures (ie, very mildly affected vs extremely critical patients at presentation). Last, there are 2 main operational definitions of frailty, the physical phenotype and the multidomain phenotype. The physical phenotype—described by Fried et al as the presence of unintentional weight loss, exhaustion, weakness, slow walking speed, and low level of physical activity—was difficult to derive in our acute hospital patients. For this reason, we assessed frailty using the mFI.
Conclusions and Implications

Almost 1 in 2 patients ≥75 years diagnosed with COVID-19 died during hospitalization. Functional profile at 2 weeks before disease and assessment of frailty seem to be important factors in determining the in-hospital prognosis irrespective of age and comorbidities and help to increase accuracy of the COVID-19 MRS. Older patients diagnosed with COVID-19 should be reassessed in light of their personal history, fitness, frailty, and disability so that more focused and dedicated care can be provided.

References

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–269.
2. Fumagalli C, Rozzini R, Vannini M, et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: A retrospective cohort study. BMJ Open 2020;10:e040729.
3. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to the hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. BMJ 2020;370:m3339.
4. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: A meta-analysis with 611,583 subjects. J Am Med Dir Assoc 2020;21:915–918.
5. Chen TL, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: A single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020;75:1788–1795.
6. Hägg S, Jylhävä J, Wang Y, et al. Age, frailty, and comorbidity as prognostic factors for short-term outcomes in patients with coronavirus disease 2019 in geriatric care. J Am Med Dir Assoc 2020;21:1555–1559.e2.
7. Policy P. Covid-19—Situazione in Italia e nel mondo. Ministero della Salute. 2020. Available at: http://www.salute.gov.it/portale/nuovocoronavirus/dettagliContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5338&area=nuovoCoronavirus&menu=vuoto. Accessed November 18, 2020.
8. WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected (v1.2). 2020. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
9. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Md State Med J 1965;14:61–65.
10. Ryg J, Engberg H, Mariadas P, et al. Barthel index at hospital admission is associated with mortality in geriatric patients: A Danish nationwide population-based cohort study. Clin Epidemiol 2018;10:1789–1800.
11. Saxton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg 2011;253:1223–1229.
12. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect Dis 2020;20:669–677.
13. Le Couteur DG, Anderson RM, Newman AB. COVID-19 through the lens of gerontology. J Gerontol A Biol Sci Med Sci 2020;75:e119–e120.
14. Promislow DEL, Anderson R. A geroscience perspective on COVID-19 mortality. J Gerontol A Biol Sci Med Sci 2020;75:e30–e33.
15. Smerenborg A, Peters EJ, van Dale P, et al. How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. Eur J Intern Med 2021;83:1–5.
16. López-Ortín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013;153:1194.
17. Landi F, Liperoti R, Russo A, et al. Disability, more than multimorbidity, was predictive of mortality among older persons aged 80 years and older. J Clin Epidemiol 2010;63:752–759.
18. De Smet R, Mellaerts B, Vandevenneke H, et al. Frailty and mortality in hospitalized older adults with COVID-19: Retrospective observational study. J Am Med Dir Assoc 2020;21:928–932.e1.
19. Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. Lancet 2015;385:549–562.
20. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5,000 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052–2059.
21. Chen R, Liang W, Jiang M, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest 2020;158:97–105.
22. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
23. Torres OH, Muñoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: Importance of functional assessment. J Am Geriatr Soc 2004;52:1603–1609.
24. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–M157.
25. Theou O, Squires E, Mallory K, et al. What do we know about frailty in the acute care setting? A scoping review. BMC Geriatr 2018;18:139.
26. Baldasseroni S, Pratesi A, Stefano P, et al. Pre-operative physical performance as a predictor of in-hospital outcomes in older patients undergoing elective cardiac surgery. Eur J Intern Med 2021;84:80–87.
27. Hewitt J, Carter B, Vilches-Mora García J, et al. The effect of frailty on survival in patients with COVID-19 (COPE): A multicentre, European, observational cohort study. Lancet Public Health 2020;5:e444–e451.
28. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934–943.
29. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054–1062.
30. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–M156.
# Supplementary Table 1

## Laboratory, Imaging Findings on Admission and Treatment Strategies by Survival Status

| Overall (N = 221) | Nonsurvivors (n = 97) | Survivors (n = 124) | P |
|-------------------|-----------------------|---------------------|---|
| **Laboratory findings** | | | |
| PaO2/FiO2 | 260 (204-406) | 230 (161-265) | 288 (250-331) | <.001 |
| PaO2/FiO2 < 200, n (%) | 54 (24.4) | 36 (37.1) | 18 (14.5) | <.001 |
| Hematocrit, % | 40 (36-44) | 39 (35-43) | 41 (37-44) | .039 |
| Hemoglobin, g/dL | 12.8 (11.4-13.9) | 12.8 (11.2-13.9) | 12.9 (11.5-13.9) | .64 |
| WBC, ×10^9/L | 7.00 (5.00-9.54) | 7.79 (5.2-10.60) | 6.83 (4.93-8.42) | .022 |
| Lymphocytes, ×10^9/L | 0.82 (0.56-1.12) | 0.77 (0.51-1.08) | 0.84 (0.63-1.19) | .013 |
| Lymphocytopenia, n (%) | 151 (68.9) | 70 (72.2) | 81 (66.4) | .36 |
| Platelets, ×10^9/L | 187 (138-236) | 159 (118-221) | 201 (160-247) | <.001 |
| ALT, U/L | 22 (15-34) | 25 (16-39) | 20 (14-32) | .15 |
| AST, U/L | 38 (25-60) | 45 (34-72) | 31 (22-48) | .022 |
| Serum creatinine, mg/dL | 1.10 (0.81-1.54) | 1.23 (0.92-1.84) | 0.98 (0.77-1.33) | <.001 |
| CPK, U/L | 103 (75-158) | 130 (78-262) | 86 (47-160) | .013 |
| CRP, mg/L | 247 (145-481) | 347 (247-500) | 277 (222-371) | <.001 |
| CRP, mg/L | 93 (47-159) | 134 (66-188) | 68 (36-137) | <.001 |
| ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatine phosphokinase; CRP, C-reactive protein; IL-6, interleukin-6; LDH, lactate dehydrogenase; TNF-α, tumor necrosis factor alpha; WBC, white blood cell.

## Imaging: Chest radiograph, n (%)

| Imaging | Nonsurvivors (n = 91) | Survivors (n = 122) | P |
|---------|-----------------------|---------------------|---|
| Negative | 18 (8.5) | 13 (10.7) | .26 |
| Consolidation | 40 (18.8) | 26 (21.3) | .64 |
| Interstitial | 123 (57.7) | 64 (52.5) | |
| Mixed | 32 (15) | 19 (15.6) | |

## Treatment strategies, n (%)

| Therapy | Nonsurvivors (n = 97) | Survivors (n = 124) | P |
|---------|-----------------------|---------------------|---|
| Respiratory support | | | |
| None | 7 (3.2) | 6 (4.8) | .006 |
| Oxygen | 176 (79.6) | 105 (84.7) | .11 |
| Noninvasive ventilation | 26 (11.8) | 7 (5.6) | .011 |
| Invasive ventilation | 12 (5.5) | 6 (4.8) | | |
| Drugs | | | |
| Antibiotics | 181 (81.9) | 94 (75.8) | .008 |
| Heparin | 143 (64.7) | 94 (75.8) | .013 |
| Hydroxychloroquine | 110 (49.8) | 73 (58.9) | .002 |
| Lopinavir or ritonavir | 107 (48.4) | 73 (58.9) | .001 |
| Corticosteroids | 71 (32.1) | 32 (23.8) | .023 |

 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatine phosphokinase; CRP, C-reactive protein; IL-6, interleukin-6; LDH, lactate dehydrogenase; TNF-α, tumor necrosis factor alpha; WBC, white blood cell.

Unless otherwise noted, values are median (interquartile range).

# Supplementary Table 2

## Treatment Strategies by Barthel Index

| Treatment Strategies | Barthel Index ≤75 (n = 102) | Barthel Index >75 (n = 119) | P |
|----------------------|-----------------------------|-----------------------------|---|
| Respiratory support | | | |
| None | 2 (2.0) | 5 (4.2) | .63 |
| Oxygen | 82 (80.4) | 94 (79.0) | |
| Noninvasive ventilation | 11 (10.8) | 15 (12.6) | |
| Invasive ventilation | 7 (3.2) | 5 (4.2) | |
| Drugs | | | |
| Antibiotics | 79 (77.5) | 102 (85.7) | .11 |
| Heparin | 64 (62.7) | 79 (66.4) | .57 |
| Hydroxychloroquine | 58 (56.9) | 52 (43.7) | .05 |
| Lopinavir or ritonavir | 56 (54.9) | 51 (42.9) | .07 |
| Corticosteroids | 40 (39.2) | 31 (26.1) | .037 |

 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatine phosphokinase; CRP, C-reactive protein; IL-6, interleukin-6; LDH, lactate dehydrogenase; TNF-α, tumor necrosis factor alpha; WBC, white blood cell.

Unless otherwise noted, values are median (interquartile range).